Observational Study About Patients Diagnosed With NAFLD
ConditionNonalcoholic Fatty Liver Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorXiangya Hospital of Central South University
About this trial
Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome. The largest study to date using magnetic resonance spectroscopy to quantify liver triglyceride (TG) content showed that approximately 33% of individuals have hepatic steatosis. NAFLD encompasses a continuum of histological findings that starts with steatosis that can progress to nonalcoholic steatohepatitis (NASH), which is characterized by inflammation and cell death, and eventually cirrhosis. Given the large number of individuals afflicted with this condition, there is a clear need to develop effective and safe therapies to treat NAFLD.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
patients suspected of excessive alcohol consumption
malignant tumors, dementia, active tuberculosis, AIDS, organ failure, pregnancy or breastfeeding, etc cannot cooperate with the investigation
incomplete data such as HBV serological results and abdominal ultrasound results
patients who refuse to sign informed consent
Trial population
Patients between the age of 18-75, who was diagnosed with NAFLD were all elligible for this observational study.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
500 Participants
are grouped into 1 trial groupGroup A: Patients diagnosed with NAFLD
Trial outcomes
Primary outcomes
1
BMI
BMI stands for body mass index. This is the ratio of a person's height to their weight.
Time frame
3 weeks2
alcohol intake
alcohol consumption every week
Time frame
3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov